Drawing for BIOSENIC

USPTO serial 79368558

BIOSENIC

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
MARTIN, CHRISTINE C
Law office
TMEG LAW OFFICE 104

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with BIOSENIC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations; medical preparations; biotechnological preparations for medical use; chemical preparations for medical use; chemical preparations for pharmaceutical use; pharmaceutical implants; biological implants; implants comprising living tissue; cell, gene and protein-based therapy products for treating and preventing musculoskeletal indications and inflammatory related diseases; pharmaceutical products for the treatment of bone diseases or disorders and inflammatory related diseases; bone-forming cells for bone fracture repair, fracture prevention and bone fusion; cell therapy products for the treatment of bone diseases or disorders; allogeneic osteoblastic cell therapy products; tissue and bone-regenerative pharmaceutical preparations; biological tissue cultures for medical purposes; natural biomaterials for augmentation of bone and tissue for medical purposes; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, bone diseases and disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Sep 23, 2024MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Sep 23, 2024ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 22, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jan 8, 2024RFNTREFUSAL PROCESSED BY IB—
Dec 21, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 21, 2023RFRRREFUSAL PROCESSED BY MPU—
Dec 17, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 16, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 12, 2023DOCKASSIGNED TO EXAMINER—
May 2, 2023MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 28, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 28, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance